Most Read Articles
6 days ago
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
3 days ago
Elderly adults using hypoglycaemic glucose-lowering drugs, such as insulin and glinides, have an excess risk of hospitalization for serious trauma, a recent study has found.
Pearl Toh, 5 days ago

The duration of dual antiplatelet therapy (DAPT) should be individualized based on ischaemic and bleeding risk of a particular patient, rather than focusing on a dualistic short- vs long-duration therapy thinking, advocates a leading expert during AFCC 2018.

07 Oct 2018
Patients using long-acting opioids with immunosuppressive properties are at greater risk of developing serious infections compared with those using the nonimmunosuppressive opioid counterpart, according to a study.

BP-BES better than DP-DES at reducing adverse events, stent thrombosis

14 Nov 2017

BP-BES (biodegradable polymer biolimus-eluting stents) leads to lower rates of target lesion revascularization (TLR), major adverse cardiac events (MACE) and stent thrombosis (ST) at 5 years compared with DP-DES (durable polymer drug-eluting stents), according to a new meta-analysis.

After applying the selection criteria, the meta-analysis was performed on five studies corresponding to 4,687 patients. The studies were retrieved from the databases of the Cochrane Library, Embase and PubMed.

Pooled data from four trials showed that BP-BES significantly reduced the risk of MACE compared to first-generation DP-DES (odds ratio [OR], 0.80; 95 percent CI, 0.68 to 0.95; p=0.01). In contrast, the risk of MACE was not significantly different between BP-BES and second-generation DP-DES (OR, 0.96; 0.68 to 1.37p =0.38).

Overall, however, BP-BES significantly reduced the risk of MACE compared with DP-DES (OR, 0.83; 0.71 to 0.97; p=0.02). Similarly, BP-BES significantly reduced the risk of TLR compared to first-generation (OR, 0.73; 0.58 to 0.92; p=0.008) but not second-generation (OR, 1.34; 0.63 to 2.83; p=0.44) DP-DES. Overall, BP-BES was better than DP-DES in reducing the risk of TLR (OR, 0.77; 0.62 to 0.96; p=0.02).

BP-BES was again superior to first-generation (OR, 0.57; 0.39 to 0.82; p=0.002) but not second-generation (OR, 87; 0.35 to 2.16; p=0.76) DP-DES in reducing the risk of ST. Overall, the risk of ST was significantly lower with BP-BES than DP-DES (OR, 0.60; 0.43 to 0.84; p=0.003).

On the other hand, BP-BES showed no clear advantage over DP-DES in reducing the risk of death (OR, 0.89; 0.72 to 1.11; p=0.30), myocardial infarctions (OR, 0.88; 0.70 to 1.10; p=0.27) and target vessel revascularization (OR, 0.89; 0.73 to 1.08; p=0.23).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
3 days ago
Elderly adults using hypoglycaemic glucose-lowering drugs, such as insulin and glinides, have an excess risk of hospitalization for serious trauma, a recent study has found.
Pearl Toh, 5 days ago

The duration of dual antiplatelet therapy (DAPT) should be individualized based on ischaemic and bleeding risk of a particular patient, rather than focusing on a dualistic short- vs long-duration therapy thinking, advocates a leading expert during AFCC 2018.

07 Oct 2018
Patients using long-acting opioids with immunosuppressive properties are at greater risk of developing serious infections compared with those using the nonimmunosuppressive opioid counterpart, according to a study.